TY  - JOUR
T1  - Tirofiban'a Bağlı Diffüz Alveolar Hemoraji ECMO ile Tedavi Edilebilir mi?
TT  - Is Diffuse Alveolar Haemorrhage due to Tirofiban Treated with ECMO?
AU  - Kerkütlüoğlu, Murat
AU  - Güneş, Hakan
AU  - Eroğlu, Erdinç
PY  - 2019
DA  - March
Y2  - 2018
DO  - 10.17517/ksutfd.442705
JF  - Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
JO  - KSU Medical Journal
PB  - Kahramanmaras Sutcu Imam University
WT  - DergiPark
SN  - 1303-6610
SP  - 39
EP  - 41
VL  - 14
IS  - 1
LA  - tr
AB  - Akut koroner sendromlarıngelişmesinde trombositler aktif rol oynar. Trombosit inaktivitesi içinkullanılan Glikoprotein (GP) IIb / IIIa inhibitörlerinin Perkütan KoronerGirişim (PCI) sırasında kullanımı iskemik komplikasyonlardan korunmada kritiköneme sahipken major kanamalarada yol açabilir. Diffüz alveoler kanama da,glikoprotein IIb / IIIa inhibitörlerinin sebep olabileceği nadir ancak yaşamıtehdit eden, tanı konması ve tedavisi güç bir komplikasyondur.Biz de olgumuzda46 yaşında akut inferior miyokard infarktüsü nedeni ile primer PCI işlemiyapılan ve tirofiban tedavisi sonrası diffüz alveolar hemoraji gelişen, ECMOcihaz uygulaması ile tedavi etmeye çalıştığımız hastamızı sunuyoruz
KW  - tirofiban
KW  - diffüz alveolar hemoraji
KW  - ECMO
N2  - Thrombocytes play an active role inthe development of acute coronary syndromes. The use of Glycoprotein (II) IIb /IIIa inhibitors for platelet inactivity during Percutaneous CoronaryIntervention (PCI) may lead to major cancers with critical preservation ofischemic complications. Diffuse alveolar hemorrhage is a rare butlife-threatening complication that can be caused by glycoprotein IIb / IIIainhibitors. We have a 46-year-old woman with acute inferior myocardialinfarction who underwent primary PCI and developed diffuse alveolar haemorrhageafter tirofiban therapy. We present the patientare trying to treat with ECMO device application.
CR  - 1.Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017 Aug 26.
CR  - 2. Conley M, Patino G, Romick B, Almaleh M, Campbell C, Hawkins K, et al. Abciximab-induced alveolar hemorrhage Texas Heart Institute Journal Diffuse Alveolar Hemorrhage 103 after percutaneous coronary intervention. Can J Cardiol 2008;24(2):149-51.
CR  - 3.S.R Steinbuhl, J.D Talley, G.A Braden, et al.Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the gold (au-assessing ultegra) multicenter study Circulation, 103 (2001), pp. 2572-257
CR  - 4.S.M. Albelda, W.B. Gefter, D.M. Epstein, W.T. MillerDiffuse pulmonary hemorrhage: a review and classification Radiology, 154 (2) (1985), pp. 289-297
CR  - 5 .Yilmaz MB, Akin Y, Biyikoglu SF, Guray U, Korkmaz S. Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication. Int J Cardiol 2004;93(1):81-2.
CR  - 6 .Gill DS, Ng K, Ng KS. Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome. Heart 2004;90(3):e15.
CR  - 7 .Fernandez-Perez GC, Vazquez M, Delgado C, Velasco M, Vazquez-Lima A, Rodriguez-Perez J. Pulmonary hemorrhage in a patient with acute coronary syndrome. AJR Am J Roentgenol 2007;189(3):W135-7.
CR  - 8.Ener RA, Bruno N, Dadourian D, Wolf N, Van Decker W, Burke J, et al. Alveolar hemorrhage associated with platelet glycoprotein IIb/IIIa receptor inhibitors. J Invasive Cardiol 2006;18(6):254-61.
CR  - 9 .Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J. 2012;39(1):99-103. Review.
CR  - 10.Mosier J, Kelsey M, Raz Y, vd. Extracorporeal membrane oxygenation (ECMO) for critically ill adults in the emergency department: history, current applications, and future directions. Crit Care. 2015;19:431.
UR  - https://doi.org/10.17517/ksutfd.442705
L1  - https://dergipark.org.tr/en/download/article-file/663909
ER  -